Whitehead, Michael http://orcid.org/0000-0002-5494-8302
Sage, Andrew
Burgoyne, Tom
Osborne, Andrew
Yu-Wai-Man, Patrick
Martin, Keith R. http://orcid.org/0000-0002-9347-3661
Funding for this research was provided by:
National Eye Research Centre (G104353)
CUH | Addenbrooke's Charitable Trust, Cambridge University Hospitals (G109216)
Wellcome Trust (104001/Z/14/Z)
Article History
Received: 23 August 2022
Revised: 22 May 2023
Accepted: 12 June 2023
First Online: 29 June 2023
Competing interests
: AO is an employee of Ikarovec Ltd, a company developing gene therapy technologies. PY is a consultant for Gensight Biologics. KGM is a founder of Quethera Ltd, a gene therapy company acquired by Astellas Pharma. MW and AS declare no competing interests.
: All procedures performed on animals were approved by the UK Home Office in accordance with the UK Animals (Scientific Procedures) Act, and undertaken in accordance with the Association for Research in Vision and Ophthalmology’s (ARVO) Statement for the Use of Animals in Ophthalmic and Visual Research. The sample size used in each experiment is stipulated in the figure legends.